[1] Herrmann T, Karunakaran MM. Phosphoantigen recognition by Vγ9Vδ2 T cells[J]. Eur J Immunol, 2024, 54: 2451068.doi:10.1002/eji.202451068. [2] Rigau M, Ostrouska S, Fulford TS, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells[J]. Science, 2020, 367: eaay5516.doi:10.1126/science.aay5516. [3] Hayday A, Dechanet-Merville J, Rossjohn J, et al. Cancer immunotherapy by γδ T cells[J]. Science, 2024, 386: eabq7248.doi:10.1126/science.abq7248. [4] Harly C, Joyce SP, Domblides C, et al. Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramm-ing through TCR recognition of EphA2[J]. Sci Immunol, 2021, 6: eaba9010.doi:10.1126/sciimmunol.aba9010. [5] Willcox CR, Pitard V, Netzer S, et al. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor[J]. Nat Immunology, 2012, 13: 872-879. [6] Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I[J]. Immunity, 2005, 22: 71-80. [7] Marlin R, Pappalardo A, Kaminski H, et al. Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2[J]. Proc Natl Acad Sci U S A, 2017, 114: 3163-3168. [8] You H, Zhang X, Chen H, et al. γδ T-cell autoresponses to ectopic membrane proteins: a new type of pattern recognition[J]. Cell Mol Immunol, 2025: 1-15. [9] Dai Y, Chen H, Mo C, et al. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity[J]. J Biol Chem, 2012, 287: 16812-16819. [10] Ji J, Shen J, Xu Y, et al. FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development[J]. Cell Death Dis, 2022, 13: 1-9. [11] Che X, Jian F, Wang Y, et al. FBXO2 promotes proliferation of endometrial cancer by ubiquitin-mediated degradation of FBN1 in the regulation of the cell cycle and the autophagy pathway[J]. Front Cell Dev Biol., 2020, 8: 843. doi:10.3389/fcell.2020.00843. [12] Wang Y, Han J, Wang D, et al. Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer[J]. Signal Transduct Target Ther, 2023, 8: 1-11. [13] Huang SW, Pan CM, Lin YC, et al. BiTE-secreting CAR-γδ T as a dual targeting strategy for the treatment of solid tumors[J]. Adv Sci (Weinh), 2023, 10: 2206856.doi:10.1002/advs.202206856. |